HCW Biologics Inc.
HCWB
$2.06
$0.073.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -87.93% | -78.77% | -63.19% | -9.68% | 22.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -87.93% | -78.77% | -63.19% | -9.68% | 22.27% |
| Cost of Revenue | -85.71% | -75.33% | -60.23% | -29.55% | 3.49% |
| Gross Profit | -92.55% | -86.37% | -70.26% | 71.23% | 96.70% |
| SG&A Expenses | -65.42% | -64.29% | -4.21% | 29.19% | 130.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -60.27% | -60.08% | -13.80% | 12.19% | 67.32% |
| Operating Income | 57.57% | 58.11% | 6.84% | -14.61% | -73.56% |
| Income Before Tax | 67.72% | 70.29% | 9.63% | -20.12% | -89.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 67.72% | 70.29% | 9.63% | -20.12% | -89.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.72% | 70.29% | 9.63% | -20.12% | -89.19% |
| EBIT | 57.57% | 58.11% | 6.84% | -14.61% | -73.56% |
| EBITDA | 61.11% | 61.24% | 8.16% | -15.08% | -78.40% |
| EPS Basic | 65.26% | 61.32% | 15.71% | -13.26% | -82.72% |
| Normalized Basic EPS | 69.52% | 64.24% | 10.26% | -12.23% | -74.88% |
| EPS Diluted | 65.26% | 61.32% | 15.71% | -13.26% | -81.15% |
| Normalized Diluted EPS | 69.52% | 64.24% | 10.26% | -12.23% | -74.88% |
| Average Basic Shares Outstanding | 66.98% | 33.36% | 12.11% | 7.97% | 3.68% |
| Average Diluted Shares Outstanding | 66.98% | 33.36% | 12.11% | 7.97% | 3.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |